Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.01
13% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $907.0K | $456.0K | $341.0K | $154.0K | $510.0K | $636.0K | $1.1M |
| Cost of revenue | $693.0K | $468.0K | $622.0K | $898.0K | $38.0K | $244.0K | $347.0K | $573.0K |
| Gross profit | $493.0K | $439.0K | −$166.0K | $341.0K | $116.0K | $266.0K | $289.0K | $522.0K |
| Gross margin | 41.6% | 48.4% | -36.4% | 100.0% | 75.3% | 52.2% | 45.4% | 47.7% |
| R&D | $693.0K | $468.0K | $622.0K | $911.0K | $552.0K | $794.0K | $809.0K | $615.0K |
| Operating income | −$2.6M | −$3.7M | −$5.0M | −$7.5M | −$8.6M | −$10.2M | −$12.9M | −$11.1M |
| EBITDA | −$2.1M | −$3.0M | −$4.5M | −$6.4M | −$6.8M | −$9.8M | −$10.3M | −$9.8M |
| Net income | −$2.0M | −$2.8M | −$4.3M | −$6.7M | −$6.7M | −$10.8M | −$11.6M | −$11.2M |
| Net margin | -164.7% | -308.7% | -945.8% | -1959.5% | -4357.1% | -2122.7% | -1818.7% | -1018.5% |
| EPS (diluted) | -0.02 | -0.03 | -0.05 | -0.07 | -0.07 | -0.07 | -0.04 | -0.01 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.00 | $-0.00–$-0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
OXFORD BIODYNAMICS PLC
No one on the platform currently holds OXBOF.
No tracked institution reports a position in OXBOF as of their last filing.
No one on the platform has traded OXBOF yet.
| $14M |
| — |
| IMUCEOM Pharmaceuticals Holdings, Inc. | $0.22 | +0.00% | $28M | — |
| INTIInhibitor Therapeutics, Inc. | $0.09 | +0.00% | $16M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.4× sales vs its 54.6× historical median P/S.
Fair value ≈ $0.37 · price $0.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.